,PDB_ID,Title,Date,Entities,ChainID,Resolution,Identity,Coverage,NumGaps,GapLen,GapPos,NumLigs,NameLigs
0,1erk,structure of signal-regulated kinase,1997-05-15,1,A,2.30,355.0,99.16666666666667,1.0,[3],"[[1, 3]]",0.0,[]
1,1gol,coordinates of rat map kinase erk2 with an arginine mutation at position 52,1997-03-12,1,A,2.80,354.0,99.16666666666667,1.0,[3],"[[1, 3]]",2.0,"['ATP', 'MG']"
2,1pme,structure of penta mutant human erk2 map kinase complexed with a specific inhibitor of human p38 map kinase,1999-06-08,1,A,2.00,354.0,92.5,4.0,"[15, 3, 1, 8]","[[1, 15], [33, 35], [161, 161], [330, 337]]",3.0,"['CME', 'SB2', 'SO4']"
3,1tvo,the structure of erk2 in complex with a small molecule inhibitor,2005-09-13,1,A,2.50,360.0,97.22222222222221,2.0,"[7, 3]","[[1, 7], [358, 360]]",1.0,['FRZ']
4,1wzy,crystal structure of human erk2 complexed with a pyrazolopyridazine derivative,2005-12-20,1,A,2.50,360.0,97.22222222222221,2.0,"[7, 3]","[[1, 7], [358, 360]]",1.0,['F29']
5,2erk,phosphorylated map kinase erk2,1998-07-01,1,A,2.40,353.0,98.05555555555556,1.0,[7],"[[1, 7]]",2.0,"['PTR', 'TPO']"
6,2fys,crystal structure of erk2 complex with kim peptide derived from mkp3,2006-04-11,2,B,2.50,355.0,93.88888888888889,4.0,"[9, 8, 4, 1]","[[1, 9], [178, 185], [331, 334], [360, 360]]",0.0,[]
7,2gph,docking motif interactions in the map kinase erk2,2006-07-04,2,A,1.90,354.0,95.83333333333334,2.0,"[11, 4]","[[1, 11], [357, 360]]",0.0,[]
8,2ojg,"crystal structure of erk2 in complex with n,n-dimethyl-4-(4-phenyl-1h-pyrazol-3-yl)-1h-pyrrole-2-carboxamide",2007-02-06,1,A,2.00,360.0,93.61111111111111,3.0,"[18, 2, 3]","[[1, 18], [332, 333], [358, 360]]",2.0,"['19A', 'SO4']"
9,2oji,crystal structure of erk2 in complex with n-benzyl-4-(4-(3-chlorophenyl)-1h-pyrazol-3-yl)-1h-pyrrole-2-carboxamide,2007-02-06,1,A,2.60,360.0,95.55555555555556,2.0,"[14, 2]","[[1, 14], [359, 360]]",2.0,"['33A', 'SO4']"
10,2ojj,crystal structure of erk2 in complex with (s)-n-(1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl)-4-(4-(3-chlorophenyl)-1h-pyrazol-3-yl)-1h-pyrrole-2-carboxamide,2007-02-06,1,A,2.40,360.0,95.55555555555556,2.0,"[14, 2]","[[1, 14], [359, 360]]",2.0,"['82A', 'SO4']"
11,2y9q,crystal structure of human erk2 complexed with a mapk docking peptide,2012-02-29,2,A,1.55,360.0,96.94444444444444,3.0,"[8, 1, 2]","[[1, 8], [160, 160], [359, 360]]",1.0,['ANP']
12,2z7l,unphosphorylated mitogen activated protein kinase erk2 in complex with (4-{[5-carbamoyl-4-(3-methylanilino)pyrimidin 2-yl]amino}phenyl)acetic acid,2008-08-12,1,A,2.41,355.0,91.38888888888889,4.0,"[17, 3, 8, 3]","[[1, 17], [34, 36], [330, 337], [358, 360]]",3.0,"['BME', 'S91', 'SO4']"
13,3c9w,crystal structure of erk-2 with hypothemycin covalently bound,2008-07-08,1,A,2.50,355.0,93.33333333333333,3.0,"[7, 13, 4]","[[1, 7], [177, 189], [357, 360]]",1.0,['HMY']
14,3erk,the complex structure of the map kinase erk2/sb220025,1999-07-22,1,A,2.10,355.0,97.22222222222221,2.0,"[7, 3]","[[1, 7], [358, 360]]",1.0,['SB4']
15,3i5z,crystal structure of erk2 bound to (s)-n-(2-hydroxy-1-phenylethyl)-4-(5-methyl-2-(phenylamino)pyrimidin-4-yl)-1h-pyrrole-2-carboxamide,2010-01-12,1,A,2.20,360.0,91.94444444444444,4.0,"[7, 14, 5, 3]","[[1, 7], [174, 187], [201, 205], [358, 360]]",2.0,"['SO4', 'Z48']"
16,3i60,crystal structure of erk2 bound to (s)-4-(2-(2-chlorophenylamino)-5-methylpyrimidin-4-yl)-n-(2-hydroxy-1-phenylethyl)-1h-pyrrole-2-carboxamide,2010-01-12,1,A,2.50,360.0,93.05555555555556,4.0,"[7, 13, 3, 2]","[[1, 7], [176, 188], [202, 204], [359, 360]]",2.0,"['E86', 'SO4']"
17,3o71,crystal structure of erk2/dcc peptide complex,2011-06-15,2,A,1.95,355.0,94.44444444444444,4.0,"[10, 5, 1, 4]","[[1, 10], [177, 181], [203, 203], [357, 360]]",1.0,['SCN']
18,3qyw,crystal structure of erk2 in complex with an inhibitor,2011-08-24,1,A,1.50,354.0,94.44444444444444,4.0,"[10, 1, 5, 4]","[[1, 10], [161, 161], [332, 336], [357, 360]]",4.0,"['6PB', 'CME', 'DMS', 'SO4']"
19,3qyz,crystal structure of erk2 in complex with an inhibitor,2011-08-24,1,A,1.46,354.0,94.16666666666667,4.0,"[11, 1, 5, 4]","[[1, 11], [161, 161], [332, 336], [357, 360]]",5.0,"['BME', 'CME', 'DMS', 'SO4', 'Z8B']"
20,3r63,structure of erk2 (spe) mutant (s246e),2011-08-17,1,A,1.70,354.0,96.38888888888889,2.0,"[10, 3]","[[5, 14], [332, 334]]",0.0,[]
21,3sa0,complex of erk2 with norathyriol,2011-12-14,1,A,1.59,357.0,98.33333333333333,3.0,"[3, 2, 1]","[[1, 3], [161, 162], [254, 254]]",3.0,"['CME', 'NRA', 'SO4']"
22,3tei,crystal structure of human erk2 complexed with a mapk docking peptide,2012-08-15,2,A,2.40,358.0,94.16666666666667,4.0,"[9, 7, 3, 2]","[[1, 9], [179, 185], [202, 204], [359, 360]]",1.0,['ANP']
23,3w55,the structure of erk2 in complex with fr148083,2013-02-06,1,A,3.00,360.0,93.05555555555556,3.0,"[10, 12, 3]","[[1, 10], [176, 187], [358, 360]]",1.0,['1FM']
24,3zu7,crystal structure of a designed selected ankyrin repeat protein in complex with the map kinase erk2,2012-06-27,2,A,1.97,355.0,95.55555555555556,2.0,"[11, 5]","[[1, 11], [356, 360]]",0.0,[]
25,3zuv,crystal structure of a designed selected ankyrin repeat protein in complex with the phosphorylated map kinase erk2,2012-06-27,2,A,2.72,353.0,99.72222222222223,1.0,[1],"[[8, 8]]",3.0,"['PTR', 'SO4', 'TPO']"
26,4erk,the complex structure of the map kinase erk2/olomoucine,1999-07-22,1,A,2.20,355.0,97.22222222222221,2.0,"[7, 3]","[[1, 7], [358, 360]]",2.0,"['OLO', 'SO4']"
27,4fmq,crystal structure of human erk2 complexed with a mapk docking peptide,2012-10-31,2,A,2.10,360.0,97.22222222222221,2.0,"[8, 2]","[[1, 8], [359, 360]]",1.0,['ANP']
28,4fux,crystal structure of the erk2 complexed with e75,2012-08-22,1,A,2.20,359.0,95.0,4.0,"[10, 1, 4, 3]","[[1, 10], [161, 161], [332, 335], [358, 360]]",4.0,"['CME', 'E75', 'EDO', 'SO4']"
29,4fuy,crystal structure of the erk2 complexed with ek2,2012-08-22,1,A,2.00,357.0,91.38888888888889,6.0,"[13, 6, 2, 1, 7, 2]","[[1, 13], [58, 63], [161, 162], [254, 254], [332, 338], [359, 360]]",4.0,"['CME', 'EDO', 'EK2', 'SO4']"
30,4fv0,crystal structure of the erk2 complexed with ek3,2012-08-22,1,A,2.10,357.0,94.72222222222221,5.0,"[10, 2, 1, 4, 2]","[[1, 10], [161, 162], [254, 254], [332, 335], [359, 360]]",4.0,"['CME', 'EDO', 'EK3', 'GOL']"
31,4fv1,crystal structure of the erk2 complexed with ek4,2012-08-22,1,A,1.99,359.0,95.0,4.0,"[10, 1, 3, 4]","[[1, 10], [161, 161], [331, 333], [357, 360]]",5.0,"['CME', 'EDO', 'EK4', 'GOL', 'SO4']"
32,4fv2,crystal structure of the erk2 complexed with ek5,2012-08-29,1,A,2.00,359.0,95.55555555555556,4.0,"[10, 1, 2, 3]","[[1, 10], [161, 161], [332, 333], [358, 360]]",5.0,"['CME', 'EDO', 'EK5', 'GOL', 'SO4']"
33,4fv3,crystal structure of the erk2 complexed with ek6,2012-08-29,1,A,2.20,359.0,96.11111111111111,3.0,"[10, 1, 3]","[[1, 10], [161, 161], [358, 360]]",4.0,"['CME', 'EDO', 'EK6', 'SO4']"
34,4fv4,crystal structure of the erk2 complexed with ek7,2012-08-29,1,A,2.50,359.0,91.38888888888889,6.0,"[8, 2, 1, 12, 5, 3]","[[1, 8], [35, 36], [161, 161], [176, 187], [200, 204], [358, 360]]",4.0,"['CME', 'EK7', 'GOL', 'SO4']"
35,4fv5,crystal structure of the erk2 complexed with ek9,2012-08-29,1,A,2.40,359.0,91.66666666666666,5.0,"[8, 1, 14, 4, 3]","[[1, 8], [161, 161], [175, 188], [202, 205], [358, 360]]",4.0,"['CME', 'EDO', 'EK9', 'SO4']"
36,4fv6,crystal structure of the erk2 complexed with e57,2012-08-29,1,A,2.50,360.0,92.22222222222223,4.0,"[8, 14, 3, 3]","[[1, 8], [175, 188], [202, 204], [358, 360]]",3.0,"['E57', 'EDO', 'SO4']"
37,4fv7,crystal structure of the erk2 complexed with e94,2012-08-29,1,A,1.90,358.0,95.0,5.0,"[10, 1, 1, 4, 2]","[[1, 10], [161, 161], [254, 254], [332, 335], [359, 360]]",5.0,"['CME', 'E94', 'EDO', 'GOL', 'SO4']"
38,4fv8,crystal structure of the erk2 complexed with e63,2012-08-29,1,A,2.00,359.0,92.5,5.0,"[7, 1, 13, 3, 3]","[[1, 7], [161, 161], [175, 187], [202, 204], [358, 360]]",4.0,"['CME', 'E63', 'EDO', 'SO4']"
39,4fv9,crystal structure of the erk2 complexed with e71,2012-08-29,1,A,2.11,359.0,91.94444444444444,5.0,"[7, 1, 14, 4, 3]","[[1, 7], [161, 161], [175, 188], [201, 204], [358, 360]]",4.0,"['CME', 'E71', 'EDO', 'SO4']"
40,4g6n,crystal structure of the erk2,2012-09-19,1,A,2.00,359.0,94.72222222222221,4.0,"[10, 1, 6, 2]","[[1, 10], [161, 161], [330, 335], [359, 360]]",3.0,"['CME', 'EK0', 'SO4']"
41,4g6o,crystal structure of the erk2,2012-09-19,1,A,2.20,358.0,94.16666666666667,6.0,"[10, 2, 1, 1, 4, 3]","[[1, 10], [34, 35], [161, 161], [254, 254], [330, 333], [358, 360]]",4.0,"['CME', 'E28', 'EDO', 'SO4']"
42,4gsb,monoclinic crystal form of the apo-erk2,2012-09-12,1,A,1.80,353.0,95.55555555555556,4.0,"[10, 3, 1, 2]","[[1, 10], [34, 36], [161, 161], [359, 360]]",5.0,"['CME', 'CSO', 'GOL', 'PGE', 'SO4']"
43,4gt3,atp-bound form of the erk2 kinase,2012-09-12,1,A,1.68,354.0,96.38888888888889,3.0,"[10, 1, 2]","[[1, 10], [161, 161], [359, 360]]",5.0,"['ATP', 'CME', 'GOL', 'MG', 'PEG']"
44,4gva,adp-bound form of the erk2 kinase,2012-09-12,1,A,1.83,354.0,95.83333333333334,3.0,"[12, 1, 2]","[[1, 12], [161, 161], [359, 360]]",3.0,"['ADP', 'CME', 'GOL']"
45,4h3p,crystal structure of human erk2 complexed with a mapk docking peptide,2013-02-27,2,A,2.30,358.0,95.0,3.0,"[10, 7, 1]","[[1, 10], [179, 185], [360, 360]]",1.0,['ANP']
46,4h3q,crystal structure of human erk2 complexed with a mapk docking peptide,2013-02-27,2,A,2.20,356.0,97.77777777777777,1.0,[8],"[[1, 8]]",1.0,['ANP']
47,4i5h,crystal structure of a double mutant rat erk2 complexed with a type ii quinazoline inhibitor,2013-07-10,1,A,1.90,353.0,93.05555555555556,4.0,"[10, 7, 6, 2]","[[1, 10], [177, 183], [331, 336], [359, 360]]",1.0,['G17']
48,4iz5,structure of the complex between erk2 phosphomimetic mutant and pea-15,2013-04-10,2,A,3.19,352.0,96.38888888888889,2.0,"[10, 3]","[[1, 10], [358, 360]]",2.0,"['ADP', 'SO4']"
49,4iz7,structure of non-phosphorylated erk2 bound to the pea-15 death effector domain,2013-04-10,2,C,1.80,353.0,94.44444444444444,3.0,"[10, 9, 1]","[[1, 10], [177, 185], [360, 360]]",1.0,['NA']
50,4iza,structure of dually phosphorylated erk2 bound to the pea-15 death effector domain,2013-04-10,2,A,1.93,351.0,96.66666666666667,2.0,"[10, 2]","[[1, 10], [359, 360]]",2.0,"['PTR', 'TPO']"
51,4n0s,complex of erk2 with caffeic acid,2014-08-27,1,A,1.80,356.0,96.66666666666667,5.0,"[5, 1, 2, 1, 3]","[[1, 5], [65, 65], [161, 162], [254, 254], [358, 360]]",5.0,"['CME', 'DHC', 'DMS', 'PEG', 'SO4']"
52,4n4s,"a double mutant rat erk2 in complex with a pyrazolo[3,4-d]pyrimidine inhibitor",2014-04-16,1,A,2.20,353.0,95.0,3.0,"[9, 7, 2]","[[1, 9], [178, 184], [359, 360]]",1.0,['2H1']
53,4nif,heterodimeric structure of erk2 and rsk1,2014-11-12,2,B,2.15,360.0,96.94444444444444,2.0,"[8, 3]","[[1, 8], [179, 181]]",3.0,"['ANP', 'NA', 'SO4']"
54,4o6e,"discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of erk2",2014-05-21,1,A,1.95,349.0,91.11111111111111,5.0,"[12, 11, 3, 3, 3]","[[1, 12], [177, 187], [202, 204], [331, 333], [358, 360]]",1.0,['2SH']
55,4qp1,crystal structure of erk2 in complex with n-cyclohexyl-9h-purin-6-amine,2015-09-23,1,A,2.70,359.0,95.0,3.0,"[11, 1, 6]","[[1, 11], [125, 125], [330, 335]]",3.0,"['EMU', 'IMD', 'NEP']"
56,4qp2,crystal structure of erks in complex with 5-chlorobenzo[d]oxazol-2-amine,2015-09-23,1,A,2.23,359.0,93.33333333333333,5.0,"[11, 1, 6, 3, 3]","[[1, 11], [125, 125], [181, 186], [202, 204], [332, 334]]",3.0,"['36R', 'IMD', 'NEP']"
57,4qp3,crystal structure of erk2 in complex with (s)-2-((9h-purin-6-yl)amino)-3-phenylpropan-1-ol,2015-09-23,1,A,2.60,359.0,94.16666666666667,4.0,"[11, 1, 6, 3]","[[1, 11], [125, 125], [181, 186], [202, 204]]",2.0,"['36Q', 'NEP']"
58,4qp4,crystal structure of erk2 in complex with n-cyclohexyl-9h-purin-6-amine,2015-09-23,1,A,2.20,360.0,93.61111111111111,3.0,"[12, 8, 3]","[[1, 12], [176, 183], [358, 360]]",1.0,['36O']
59,4qp6,"crystal structure of erk2 in complex with 5h-pyrrolo[2,3-b]pyrazine",2015-09-23,1,A,3.10,359.0,94.16666666666667,4.0,"[11, 1, 6, 3]","[[1, 11], [125, 125], [181, 186], [202, 204]]",3.0,"['36N', 'IMD', 'NEP']"
60,4qp7,"crystal structure of erk2 in complex with 2-(1h-pyrazol-4-yl)-5h-pyrrolo[2,3-b]pyrazine",2015-09-23,1,A,2.25,360.0,93.61111111111111,3.0,"[12, 8, 3]","[[1, 12], [176, 183], [358, 360]]",1.0,['363']
61,4qp8,"crystal structure of erk2 in complex with 2-(1h-pyrazol-4-yl)-7-(pyridin-3-yl)-5h-pyrrolo[2,3-b]pyrazine",2015-09-23,1,A,2.45,360.0,93.05555555555556,3.0,"[11, 11, 3]","[[1, 11], [175, 185], [358, 360]]",1.0,['362']
62,4qp9,"crystal structure of erk2 in complex with 7-(1-propyl-1h-pyrazol-4-yl)-2-(pyridin-4-yl)-5h-pyrrolo[2,3-b]pyrazine",2015-09-23,1,A,2.00,360.0,93.05555555555556,4.0,"[12, 8, 2, 3]","[[1, 12], [176, 183], [332, 333], [358, 360]]",1.0,['35X']
63,4qpa,"crystal structure of erk2 in complex with 7-(1-benzyl-1h-pyrazol-4-yl)-2-(pyridin-4-yl)-5h-pyrrolo[2,3-b]pyrazine",2015-09-23,1,A,2.85,359.0,91.94444444444444,5.0,"[14, 1, 3, 8, 3]","[[1, 14], [125, 125], [181, 183], [248, 255], [358, 360]]",2.0,"['35W', 'NEP']"
64,4qta,structure of human erk2 in complex with sch772984 revealing a novel inhibitor-induced binding pocket,2014-07-23,1,A,1.45,360.0,93.05555555555556,3.0,"[9, 14, 2]","[[1, 9], [176, 189], [359, 360]]",3.0,"['38Z', 'EDO', 'SO4']"
65,4qte,"structure of erk2 in complex with vtx-11e, 4-{2-[(2-chloro-4-fluorophenyl)amino]-5-methylpyrimidin-4-yl}-n-[(1s)-1-(3-chlorophenyl)-2-hydroxyethyl]-1h-pyrrole-2-carboxamide",2014-07-23,1,A,1.50,360.0,96.66666666666667,2.0,"[10, 2]","[[1, 10], [359, 360]]",4.0,"['390', 'CL', 'EDO', 'SO4']"
66,4qyy,"discovery of novel, dual mechanism erk inhibitors by affinity selection screening of an inactive kinase state",2014-11-12,1,A,1.65,355.0,93.61111111111111,3.0,"[14, 4, 5]","[[1, 14], [331, 334], [356, 360]]",2.0,"['3G7', 'SO4']"
67,4s2z,erk2 intrinsically active mutant r65s,2016-01-27,1,A,1.48,354.0,96.11111111111111,2.0,"[10, 4]","[[5, 14], [357, 360]]",0.0,[]
68,4s30,erk2 intrinsically active mutant (i84a),2016-01-27,1,A,2.00,354.0,95.0,4.0,"[11, 1, 3, 3]","[[5, 15], [36, 36], [335, 337], [358, 360]]",0.0,[]
69,4s31,crystal structure of mitogen-activated protein kinase 1 wterk2 at 1.45a,2016-01-27,1,A,1.45,355.0,96.38888888888889,2.0,"[10, 3]","[[5, 14], [358, 360]]",0.0,[]
70,4s32,crystal structure of erk2 amp-pnp complex,2016-01-27,1,A,1.34,355.0,96.11111111111111,2.0,"[10, 4]","[[5, 14], [357, 360]]",3.0,"['ANP', 'MG', 'SO4']"
71,4s33,erk2 r65s mutant complexed with amp-pnp,2016-01-27,1,A,1.48,354.0,96.38888888888889,2.0,"[10, 3]","[[5, 14], [358, 360]]",3.0,"['ANP', 'MG', 'SO4']"
72,4s34,erk2 (i84a) in complex with amp-pnp,2016-01-27,1,A,2.50,354.0,95.27777777777777,3.0,"[10, 3, 4]","[[5, 14], [332, 334], [357, 360]]",3.0,"['ANP', 'MG', 'SO4']"
73,4xj0,crystal structure of erk2 in complex with an inhibitor 14k,2015-09-16,1,A,2.58,348.0,95.83333333333334,4.0,"[11, 1, 1, 2]","[[1, 11], [125, 125], [258, 258], [332, 333]]",2.0,"['41B', 'NEP']"
74,4xne,crystal structure of erk2 in complex with an inhibitor,2015-08-12,1,A,1.80,343.0,95.55555555555556,4.0,"[10, 1, 1, 4]","[[1, 10], [161, 161], [254, 254], [357, 360]]",3.0,"['CME', 'SO4', 'TT4']"
75,4xoy,crystal structure of erk2 in complex with an inhibitor,2015-08-12,1,A,2.10,346.0,90.55555555555556,8.0,"[10, 5, 1, 2, 3, 1, 7, 5]","[[1, 10], [58, 62], [127, 127], [161, 162], [186, 188], [254, 254], [330, 336], [356, 360]]",3.0,"['CME', 'DX4', 'SO4']"
76,4xoz,crystal structure of erk2 in complex with an inhibitor,2015-08-12,1,A,1.95,349.0,94.72222222222221,4.0,"[9, 1, 5, 4]","[[1, 9], [161, 161], [332, 336], [357, 360]]",3.0,"['620', 'CME', 'SO4']"
77,4xp0,crystal structure of erk2 in complex with an inhibitor,2015-08-12,1,A,1.46,346.0,93.33333333333333,6.0,"[9, 1, 2, 1, 7, 4]","[[1, 9], [127, 127], [161, 162], [254, 254], [330, 336], [357, 360]]",4.0,"['42A', 'CME', 'DMS', 'SO4']"
78,4xp2,crystal structure of erk2 in complex with an inhibitor,2015-08-12,1,A,1.75,348.0,93.61111111111111,5.0,"[9, 1, 1, 7, 5]","[[1, 9], [161, 161], [254, 254], [332, 338], [356, 360]]",4.0,"['CME', 'DMS', 'SO4', 'TT4']"
79,4xp3,crystal structure of erk2 in complex with an inhibitor,2015-08-12,1,A,1.78,348.0,94.16666666666667,5.0,"[9, 1, 1, 6, 4]","[[1, 9], [161, 161], [254, 254], [332, 337], [357, 360]]",4.0,"['CME', 'DMS', 'DX4', 'SO4']"
80,4xrj,crystal structure of erk2 in complex with an inhibitor,2015-08-12,1,A,1.69,343.0,95.55555555555556,4.0,"[10, 1, 1, 4]","[[1, 10], [161, 161], [254, 254], [357, 360]]",3.0,"['620', 'CME', 'SO4']"
81,4xrl,crystal structure at room temperature of erk2 in complex with an inhibitor,2016-03-23,1,A,2.55,341.0,93.61111111111111,4.0,"[10, 1, 7, 5]","[[1, 10], [161, 161], [330, 336], [356, 360]]",3.0,"['42A', 'CME', 'SO4']"
82,4zxt,complex of erk2 with catechol,2016-05-25,1,A,2.00,357.0,96.66666666666667,4.0,"[6, 2, 1, 3]","[[1, 6], [161, 162], [254, 254], [358, 360]]",4.0,"['CAQ', 'CME', 'NH4', 'SO4']"
83,4zzm,human erk2 in complex with an irreversible inhibitor,2015-05-27,1,A,1.89,348.0,95.55555555555556,3.0,"[10, 1, 5]","[[1, 10], [161, 161], [356, 360]]",3.0,"['CME', 'CQ6', 'SO4']"
84,4zzn,human erk2 in complex with an inhibitor,2015-05-27,1,A,1.33,348.0,93.88888888888889,4.0,"[10, 1, 6, 5]","[[1, 10], [161, 161], [330, 335], [356, 360]]",3.0,"['CME', 'CQ8', 'SO4']"
85,4zzo,human erk2 in complex with an irreversible inhibitor,2015-05-27,1,A,1.63,348.0,94.16666666666667,4.0,"[10, 1, 5, 5]","[[1, 10], [161, 161], [331, 335], [356, 360]]",3.0,"['CME', 'CQ3', 'SO4']"
86,5ax3,crystal structure of erk2 complexed with allosteric and atp-competitive inhibitors.,2016-02-10,2,A,2.98,360.0,91.38888888888889,5.0,"[9, 2, 12, 6, 2]","[[1, 9], [34, 35], [182, 193], [252, 257], [359, 360]]",1.0,['5ID']
87,5bue,erk2 complexed with n-benzylpyridone tetrahydroazaindazole,2015-07-15,1,A,2.40,359.0,91.38888888888889,4.0,"[10, 15, 4, 2]","[[1, 10], [173, 187], [202, 205], [359, 360]]",2.0,"['4V8', 'NI']"
88,5bui,erk2 complexed with 2-pyridiyl tetrahydroazaindazole,2015-07-15,1,A,2.12,359.0,93.88888888888889,3.0,"[10, 10, 2]","[[1, 10], [180, 189], [359, 360]]",2.0,"['4V9', 'NI']"
89,5buj,erk2 complexed with a n-h tetrahydroazaindazole,2015-07-15,1,A,1.85,359.0,91.94444444444444,4.0,"[8, 15, 4, 2]","[[1, 8], [173, 187], [202, 205], [359, 360]]",1.0,['4VB']
90,5bvd,tetrahydropyrrolo-diazepenones as inhibitors of erk2 kinase,2015-09-09,1,A,1.90,359.0,91.66666666666666,4.0,"[8, 16, 4, 2]","[[1, 8], [174, 189], [202, 205], [359, 360]]",2.0,"['4VF', 'SO4']"
91,5bve,tetrahydropyrrolo-diazepenones as inhibitors of erk2 kinase,2015-09-09,1,A,2.00,359.0,91.66666666666666,4.0,"[8, 16, 4, 2]","[[1, 8], [174, 189], [202, 205], [359, 360]]",2.0,"['4VG', 'SO4']"
92,5bvf,tetrahydropyrrolo-diazepenones as inhibitors of erk2 kinase,2015-09-09,1,A,1.90,359.0,90.83333333333333,3.0,"[8, 23, 2]","[[1, 8], [174, 196], [359, 360]]",2.0,"['4VJ', 'SO4']"
93,5hd4,dissecting therapeutic resistance to erk inhibition rat wild type sch772984 in complex with (3r)-1-(2-oxo-2-{4-[4-(pyrimidin-2-yl)phenyl]piperazin-1-yl}ethyl)-n-[3-(pyridin-4-yl)-2h-indazol-5-yl]pyrrolidine-3-carboxamide,2016-02-24,1,A,1.45,355.0,96.38888888888889,2.0,"[10, 3]","[[1, 10], [358, 360]]",4.0,"['38Z', 'DMS', 'PG4', 'SO4']"
94,5hd7,dissecting therapeutic resistance to erk inhibition rat mutant sch772984 in complex with (3r)-1-(2-oxo-2-{4-[4-(pyrimidin-2-yl)phenyl]piperazin-1-yl}ethyl)-n-[3-(pyridin-4-yl)-2h-indazol-5-yl]pyrrolidine-3-carboxamide,2016-02-24,1,A,1.69,354.0,96.38888888888889,2.0,"[10, 3]","[[1, 10], [358, 360]]",2.0,"['38Z', 'SO4']"
95,5k4i,crystal structure of erk2 in complex with compound 22,2016-07-06,1,A,1.76,352.0,93.33333333333333,3.0,"[8, 14, 2]","[[1, 8], [176, 189], [359, 360]]",2.0,"['6QB', 'EDO']"
96,5ke0,"discovery of 1-1h-pyrazolo 4,3-c pyridine-6-yl urea inhibitors of extracellular signal regulated kinase erk for the treatment of cancers",2016-07-06,1,A,1.68,355.0,94.44444444444444,2.0,"[17, 3]","[[1, 17], [358, 360]]",2.0,"['6S9', 'SO4']"
97,5lcj,in-gel activity-based protein profiling of a clickable covalent erk 1/2 inhibitor,2016-07-20,1,A,1.78,359.0,95.83333333333334,4.0,"[10, 1, 1, 3]","[[1, 10], [161, 161], [333, 333], [358, 360]]",3.0,"['6TS', 'CME', 'SO4']"
98,5lck,a clickable covalent erk 1/2 inhibitor,2016-07-20,1,A,1.89,358.0,95.83333333333334,4.0,"[10, 1, 1, 3]","[[1, 10], [127, 127], [161, 161], [358, 360]]",3.0,"['6TT', 'CME', 'SO4']"
99,5ngu,human erk2 with an erk1/2 inhibitor,2017-04-19,1,A,2.74,358.0,94.16666666666667,4.0,"[10, 1, 5, 5]","[[1, 10], [161, 161], [332, 336], [356, 360]]",3.0,"['8X2', 'CME', 'SO4']"
100,5nhf,human erk2 with an erk1/2 inhibitor,2017-04-19,1,A,2.14,358.0,94.16666666666667,4.0,"[11, 1, 4, 5]","[[1, 11], [161, 161], [332, 335], [356, 360]]",3.0,"['8X5', 'CME', 'SO4']"
101,5nhh,human erk2 with an erk1/2 inhibitor,2017-04-19,1,A,1.94,359.0,96.66666666666667,2.0,"[10, 2]","[[1, 10], [359, 360]]",2.0,"['8XH', 'SO4']"
102,5nhj,human erk2 with an erk1/2 inhibitor,2017-04-19,1,A,2.12,359.0,95.83333333333334,2.0,"[10, 5]","[[1, 10], [356, 360]]",2.0,"['8XE', 'SO4']"
103,5nhl,human erk2 with an erk1/2 inhibitor,2017-04-19,1,A,2.07,359.0,95.83333333333334,2.0,"[10, 5]","[[1, 10], [356, 360]]",2.0,"['8XB', 'SO4']"
104,5nho,human erk2 with an erk1/2 inhibitor,2017-04-19,1,A,2.24,359.0,95.27777777777777,3.0,"[10, 2, 5]","[[1, 10], [332, 333], [356, 360]]",2.0,"['8XN', 'SO4']"
105,5nhp,human erk2 with an erk1/2 inhibitor,2017-04-19,1,A,1.99,359.0,93.88888888888889,3.0,"[10, 7, 5]","[[1, 10], [331, 337], [356, 360]]",2.0,"['8XK', 'SO4']"
106,5nhv,human erk2 with an erk1/2 inhibitor,2017-04-19,1,A,2.00,359.0,95.83333333333334,2.0,"[10, 5]","[[1, 10], [356, 360]]",2.0,"['8QB', 'SO4']"
107,5u6i,"discovery of mli-2, an orally available and selective lrrk2 inhibitor that reduces brain kinase activity",2017-03-15,1,A,1.69,355.0,94.16666666666667,3.0,"[17, 1, 3]","[[1, 17], [36, 36], [358, 360]]",2.0,"['81Y', 'SO4']"
108,5umo,structure of extracellular signal-regulated kinase,2017-03-01,1,A,2.26,355.0,96.38888888888889,2.0,"[9, 4]","[[5, 13], [357, 360]]",1.0,['SO4']
109,5v60,phospho-erk2 bound to amp-pcp,2017-07-26,1,A,2.18,351.0,96.94444444444444,2.0,"[9, 2]","[[1, 9], [359, 360]]",5.0,"['ACP', 'GOL', 'MG', 'PTR', 'TPO']"
110,5v61,phospho-erk2 bound to bivalent inhibitor sbp2,2017-07-26,2,A,2.20,351.0,97.22222222222221,2.0,"[9, 1]","[[1, 9], [360, 360]]",5.0,"['90A', 'FRZ', 'GOL', 'PTR', 'TPO']"
111,5v62,phospho-erk2 bound to bivalent inhibitor sbp3,2017-07-26,2,A,1.90,349.0,97.5,1.0,[9],"[[1, 9]]",6.0,"['AKS', 'AZK', 'FRZ', 'GOL', 'PTR', 'TPO']"
112,5wp1,"complex of erk2 with 5,7-dihydroxychromone",2018-08-08,1,A,1.40,354.0,94.44444444444444,4.0,"[14, 1, 2, 3]","[[1, 14], [127, 127], [161, 162], [358, 360]]",4.0,"['B7S', 'BEZ', 'CME', 'SO4']"
113,6cpw,discovery of 3(s)-thiomethyl pyrrolidine erk inhibitors for oncology,2018-05-23,1,A,1.85,355.0,91.11111111111111,4.0,"[19, 5, 5, 3]","[[1, 19], [45, 49], [330, 334], [358, 360]]",2.0,"['F8V', 'SO4']"
114,6d5y,crystal structure of erk2 g169d mutant,2019-02-27,1,A,2.86,347.0,93.61111111111111,3.0,"[12, 8, 3]","[[1, 12], [176, 183], [358, 360]]",0.0,[]
115,6dcg,discovery of mk-8353: an orally bioavailable dual mechanism erk inhibitor for oncology,2018-08-08,1,A,1.45,355.0,90.55555555555556,4.0,"[17, 5, 8, 4]","[[1, 17], [45, 49], [330, 337], [357, 360]]",2.0,"['G67', 'SO4']"
116,6dmg,a multiconformer ligand model of ek6 bound to erk2,2018-12-19,1,A,2.20,346.0,96.11111111111111,3.0,"[10, 1, 3]","[[1, 10], [161, 161], [358, 360]]",4.0,"['CME', 'EDO', 'EK6', 'SO4']"
117,6fi3,crystal structure of erk2 in complex with an adenosine derivative,2019-01-30,1,A,1.52,354.0,93.61111111111111,4.0,"[10, 1, 7, 5]","[[1, 10], [161, 161], [331, 337], [356, 360]]",4.0,"['CME', 'DJ2', 'DMS', 'SO4']"
118,6fi6,crystal structure of erk2 in complex with an adenosine derivative,2019-01-30,1,A,1.65,353.0,93.33333333333333,4.0,"[10, 2, 8, 4]","[[1, 10], [161, 162], [330, 337], [357, 360]]",4.0,"['CME', 'DF8', 'DMS', 'SO4']"
119,6fj0,crystal structure of erk2 in complex with an adenosine derivative,2019-01-30,1,A,1.66,354.0,94.16666666666667,4.0,"[10, 1, 5, 5]","[[1, 10], [161, 161], [332, 336], [356, 360]]",4.0,"['A3N', 'CME', 'DMS', 'SO4']"
120,6fjb,crystal structure of erk2 in complex with an adenosine derivative,2019-02-06,1,A,1.85,354.0,93.33333333333333,4.0,"[11, 1, 8, 4]","[[1, 11], [161, 161], [330, 337], [357, 360]]",3.0,"['AOC', 'CME', 'SO4']"
121,6fjz,crystal structure of erk2 in complex with an adenosine derivative,2019-02-06,1,A,1.86,354.0,95.83333333333334,3.0,"[10, 1, 4]","[[1, 10], [161, 161], [357, 360]]",3.0,"['CME', 'DKW', 'SO4']"
122,6fle,crystal structure of erk2 in complex with an adenosine derivative,2019-02-06,1,A,1.48,354.0,94.16666666666667,4.0,"[10, 1, 5, 5]","[[1, 10], [161, 161], [330, 334], [356, 360]]",4.0,"['CME', 'DMS', 'DQ2', 'SO4']"
123,6flv,crystal structure of erk2 in complex with an adenosine derivative,2019-02-06,1,A,1.91,354.0,95.55555555555556,4.0,"[10, 1, 1, 4]","[[1, 10], [161, 161], [334, 334], [357, 360]]",4.0,"['CME', 'DMS', 'DTW', 'SO4']"
124,6fma,crystal structure of erk2 in complex with an adenosine derivative,2019-03-13,1,A,1.67,354.0,94.44444444444444,4.0,"[10, 1, 5, 4]","[[1, 10], [161, 161], [332, 336], [357, 360]]",4.0,"['CME', 'DMS', 'DU8', 'SO4']"
125,6fn5,crystal structure of erk2 in complex with an adenosine derivative,2019-03-13,1,A,1.93,354.0,93.05555555555556,5.0,"[10, 2, 1, 8, 4]","[[1, 10], [34, 35], [161, 161], [330, 337], [357, 360]]",4.0,"['CME', 'DMS', 'DVZ', 'SO4']"
126,6fq7,crystal structure of erk2 in complex with an adenosine derivative,2019-03-13,1,A,1.60,354.0,94.72222222222221,4.0,"[10, 1, 4, 4]","[[1, 10], [161, 161], [331, 334], [357, 360]]",4.0,"['CME', 'DMS', 'E2K', 'SO4']"
127,6fr1,crystal structure of erk2 in complex with an adenosine derivative,2019-03-13,1,A,1.56,354.0,94.72222222222221,4.0,"[10, 1, 4, 4]","[[1, 10], [161, 161], [331, 334], [357, 360]]",4.0,"['CME', 'DMS', 'E3K', 'SO4']"
128,6frp,crystal structure of erk2 in complex with an adenosine derivative,2019-03-13,1,A,1.53,354.0,94.16666666666667,4.0,"[10, 1, 6, 4]","[[1, 10], [161, 161], [330, 335], [357, 360]]",4.0,"['CME', 'DMS', 'SO4', 'ZAS']"
129,6fxv,crystal structure of erk2 in complex with an adenosine derivative,2019-03-20,1,A,1.53,353.0,93.05555555555556,6.0,"[12, 1, 1, 1, 6, 4]","[[1, 12], [35, 35], [161, 161], [254, 254], [330, 335], [357, 360]]",4.0,"['CME', 'DMS', 'E9W', 'SO4']"
130,6g54,crystal structure of erk2 covalently bound to sm1-71,2019-02-27,1,A,2.05,360.0,96.38888888888889,2.0,"[9, 4]","[[1, 9], [357, 360]]",4.0,"['6H3', 'CL', 'EDO', 'SO4']"
131,6g8x,"fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2",2018-05-30,1,A,1.76,359.0,93.88888888888889,4.0,"[10, 1, 8, 3]","[[1, 10], [161, 161], [330, 337], [358, 360]]",3.0,"['CME', 'EQT', 'SO4']"
132,6g91,"fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2",2018-05-30,1,A,1.80,359.0,95.55555555555556,4.0,"[7, 1, 5, 3]","[[1, 7], [161, 161], [330, 334], [358, 360]]",3.0,"['CME', 'EQW', 'SO4']"
133,6g92,"fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2",2018-05-30,1,A,1.99,359.0,95.27777777777777,4.0,"[7, 1, 6, 3]","[[1, 7], [161, 161], [330, 335], [358, 360]]",3.0,"['CME', 'ERZ', 'SO4']"
134,6g93,"fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2",2018-05-30,1,A,1.67,359.0,95.27777777777777,4.0,"[10, 1, 3, 3]","[[1, 10], [161, 161], [332, 334], [358, 360]]",3.0,"['CME', 'EU2', 'SO4']"
135,6g97,"fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2",2018-05-30,1,A,1.90,359.0,95.55555555555556,4.0,"[10, 1, 2, 3]","[[1, 10], [161, 161], [332, 333], [358, 360]]",3.0,"['CME', 'EQZ', 'SO4']"
136,6g9a,"fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2",2018-05-30,1,A,1.91,359.0,94.72222222222221,4.0,"[7, 1, 8, 3]","[[1, 7], [161, 161], [330, 337], [358, 360]]",3.0,"['CME', 'ESQ', 'SO4']"
137,6g9d,"fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2",2018-05-30,1,A,1.80,359.0,95.83333333333334,4.0,"[7, 1, 4, 3]","[[1, 7], [161, 161], [330, 333], [358, 360]]",3.0,"['CME', 'ER8', 'SO4']"
138,6g9h,"fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2",2018-05-30,1,A,1.73,359.0,95.27777777777777,4.0,"[10, 1, 3, 3]","[[1, 10], [161, 161], [332, 334], [358, 360]]",3.0,"['CME', 'ERW', 'SO4']"
139,6g9j,"fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2",2018-05-30,1,A,1.98,357.0,96.38888888888889,4.0,"[7, 1, 2, 3]","[[1, 7], [127, 127], [161, 162], [358, 360]]",3.0,"['CME', 'ERK', 'SO4']"
140,6g9k,"fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2",2018-05-30,1,A,1.94,358.0,95.27777777777777,5.0,"[10, 1, 1, 2, 3]","[[1, 10], [127, 127], [161, 161], [332, 333], [358, 360]]",3.0,"['CME', 'ESK', 'SO4']"
141,6g9m,"fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2",2018-05-30,1,A,1.86,359.0,94.72222222222221,4.0,"[10, 1, 4, 4]","[[1, 10], [161, 161], [330, 333], [357, 360]]",3.0,"['CME', 'ESW', 'SO4']"
142,6g9n,"fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2",2018-05-30,1,A,1.76,359.0,95.55555555555556,4.0,"[10, 1, 2, 3]","[[1, 10], [161, 161], [331, 332], [358, 360]]",3.0,"['CME', 'ESN', 'SO4']"
143,6gdm,"fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2",2018-05-30,1,A,1.91,356.0,94.72222222222221,6.0,"[7, 1, 2, 1, 4, 4]","[[1, 7], [65, 65], [161, 162], [254, 254], [332, 335], [357, 360]]",4.0,"['CME', 'DMS', 'F3Z', 'SO4']"
144,6gdq,"fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2",2018-05-30,1,A,1.86,359.0,94.16666666666667,4.0,"[9, 1, 8, 3]","[[1, 9], [161, 161], [331, 338], [358, 360]]",4.0,"['CME', 'DMS', 'EVK', 'SO4']"
145,6ge0,"fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2",2018-05-30,1,A,1.82,358.0,95.27777777777777,5.0,"[10, 1, 1, 2, 3]","[[1, 10], [127, 127], [161, 161], [333, 334], [358, 360]]",4.0,"['CME', 'DMS', 'EVQ', 'SO4']"
146,6gjb,erk2 signalling protein,2019-01-02,1,A,1.82,359.0,96.38888888888889,4.0,"[7, 1, 2, 3]","[[1, 7], [161, 161], [332, 333], [358, 360]]",3.0,"['CME', 'F0H', 'SO4']"
147,6gjd,erk2 signalling protein,2019-01-02,1,A,1.58,359.0,94.72222222222221,4.0,"[9, 1, 6, 3]","[[1, 9], [161, 161], [330, 335], [358, 360]]",5.0,"['CME', 'DMS', 'F0E', 'GOL', 'SO4']"
148,6nbs,wt erk2 with compound 2507-8,2019-07-31,1,A,1.90,356.0,95.0,3.0,"[9, 5, 4]","[[1, 9], [330, 334], [357, 360]]",4.0,"['GOL', 'KJ4', 'KJ7', 'SO4']"
149,6opg,phosphorylated erk2 with amp-pnp,2019-07-31,1,A,2.90,351.0,96.94444444444444,2.0,"[9, 2]","[[1, 9], [359, 360]]",4.0,"['ANP', 'MG', 'PTR', 'TPO']"
150,6oph,phosphorylated erk2 with gdc-0994,2019-07-31,1,A,2.40,351.0,96.66666666666667,2.0,"[10, 2]","[[1, 10], [359, 360]]",3.0,"['6QB', 'PTR', 'TPO']"
151,6opi,phosphorylated erk2 with sch-cpd336,2019-07-31,1,A,3.00,351.0,90.55555555555556,5.0,"[9, 12, 5, 4, 4]","[[1, 9], [178, 189], [202, 206], [330, 333], [357, 360]]",3.0,"['N0V', 'PTR', 'TPO']"
152,6opk,phosphorylated erk2 with vertex-11e,2019-07-31,1,A,2.54,349.0,96.11111111111111,2.0,"[10, 4]","[[1, 10], [357, 360]]",3.0,"['390', 'PTR', 'TPO']"
153,6ot6,rat erk2 d319n,2019-07-10,1,A,1.65,354.0,96.11111111111111,3.0,"[10, 2, 2]","[[1, 10], [332, 333], [359, 360]]",1.0,['SO4']
154,6ots,rat erk2 e320k,2019-07-10,1,A,2.10,354.0,90.0,7.0,"[8, 2, 10, 4, 2, 8, 2]","[[1, 8], [119, 120], [175, 184], [201, 204], [255, 256], [320, 327], [359, 360]]",0.0,[]
155,6q7k,erk2 mini-fragment binding,2019-03-27,1,A,1.84,359.0,95.83333333333334,4.0,"[7, 1, 4, 3]","[[1, 7], [161, 161], [334, 337], [358, 360]]",3.0,"['2AI', 'CME', 'SO4']"
156,6q7s,erk2 mini-fragment binding,2019-06-26,1,A,1.73,359.0,94.72222222222221,4.0,"[10, 1, 4, 4]","[[1, 10], [161, 161], [330, 333], [357, 360]]",3.0,"['CME', 'IPH', 'SO4']"
157,6q7t,erk2 mini-fragment binding,2019-06-26,1,A,1.60,359.0,94.16666666666667,4.0,"[10, 1, 6, 4]","[[1, 10], [161, 161], [330, 335], [357, 360]]",3.0,"['CME', 'HOW', 'SO4']"
158,6qa1,erk2 mini-fragment binding,2019-06-26,1,A,1.58,359.0,94.72222222222221,4.0,"[10, 1, 6, 2]","[[1, 10], [161, 161], [331, 336], [359, 360]]",3.0,"['CME', 'HVK', 'SO4']"
159,6qa3,erk2 mini-fragment binding,2019-06-26,1,A,1.57,359.0,94.72222222222221,4.0,"[7, 1, 8, 3]","[[1, 7], [161, 161], [330, 337], [358, 360]]",3.0,"['CME', 'PZO', 'SO4']"
160,6qa4,erk2 mini-fragment binding,2019-06-26,1,A,1.60,359.0,93.33333333333333,5.0,"[10, 2, 1, 8, 3]","[[1, 10], [35, 36], [161, 161], [331, 338], [358, 360]]",3.0,"['CME', 'HRZ', 'SO4']"
161,6qag,erk2 mini-fragment binding,2019-03-27,1,A,2.07,359.0,94.16666666666667,4.0,"[10, 1, 7, 3]","[[1, 10], [161, 161], [331, 337], [358, 360]]",3.0,"['CME', 'HUH', 'SO4']"
162,6qah,erk2 mini-fragment binding,2019-06-26,1,A,1.58,359.0,94.16666666666667,5.0,"[10, 1, 1, 6, 3]","[[1, 10], [36, 36], [161, 161], [332, 337], [358, 360]]",3.0,"['CME', 'HVB', 'SO4']"
163,6qal,erk2 mini-fragment binding,2019-03-27,1,A,1.57,359.0,93.05555555555556,5.0,"[10, 3, 1, 8, 3]","[[1, 10], [34, 36], [161, 161], [331, 338], [358, 360]]",3.0,"['CME', 'HV2', 'SO4']"
164,6qaq,erk2 mini-fragment binding,2019-03-27,1,A,1.58,359.0,95.27777777777777,4.0,"[10, 1, 3, 3]","[[1, 10], [161, 161], [331, 333], [358, 360]]",3.0,"['CME', 'HVQ', 'SO4']"
165,6qaw,erk2 mini-fragment binding,2019-03-27,1,A,1.84,358.0,93.33333333333333,5.0,"[10, 1, 1, 9, 3]","[[1, 10], [127, 127], [161, 161], [330, 338], [358, 360]]",3.0,"['CME', 'HVE', 'SO4']"
